Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04278092
Title Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Medical University of Vienna

hypopharynx cancer

oral squamous cell carcinoma

oropharynx cancer

laryngeal squamous cell carcinoma


Cetuximab + Paclitaxel

Age Groups: adult | senior
Covered Countries AUT

No variant requirements are available.